Patents by Inventor Sarah E. Dowdell

Sarah E. Dowdell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200095217
    Abstract: Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.
    Type: Application
    Filed: October 17, 2019
    Publication date: March 26, 2020
    Inventors: Sarah E. DOWDELL, Hilary Schenck EIDAM, Mark ELBAN, Ryan Michael FOX, Marlys HAMMOND, Mark A. HILFIKER, Tram H. HOANG, Lara KALLANDER, Brian Griffin LAWHORN, Sharada MANNS, Joanne PHILP, David G. WASHBURN, Guosen YE
  • Patent number: 10450288
    Abstract: Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: October 22, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Sarah E. Dowdell, Hilary Schenck Eidam, Mark Elban, Ryan Michael Fox, Marlys Hammond, Mark A. Hilfiker, Tram H. Hoang, Lara Kallander, Brian Griffin Lawhorn, Sharada Manns, Joanne Philp, David G. Washburn, Guosen Ye
  • Publication number: 20180362485
    Abstract: Compounds of Formulas (I) and (II): and salts thereof; methods of making and using the same, including use for inhibiting BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.
    Type: Application
    Filed: July 8, 2016
    Publication date: December 20, 2018
    Inventors: Carla A. DONATELLI, Sarah E. DOWDELL, Mark ELBAN, Mark A. HILFIKER, Tram H. HOANG, Dennis Alan HOLT, Sharada MANNS, Andrew MARCUS, Craig POTTEIGER, Raynold SHENJE, David G. WASHBURN
  • Publication number: 20160340328
    Abstract: Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.
    Type: Application
    Filed: January 9, 2015
    Publication date: November 24, 2016
    Inventors: Sarah E. DOWDELL, Hilary Schenck EIDAM, Mark ELBAN, Ryan Michael FOX, Marlys HAMMOND, Mark A. HILFIKER, Tram H. HOANG, Lara KALLANDER, Brian Griffin LAWHORN, Sharada MANNS, Joanne PHILP, David G. WASHBURN, Guosen YE
  • Patent number: 8871928
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: October 28, 2014
    Assignee: Glaxo Group Limited
    Inventors: Zehong Wan, Xiaomin Zhang, Zhaolong Tong, Kai Long, Sarah E. Dowdell, Eric Steven Manas, Krista Beaver Goodman
  • Publication number: 20130178488
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.
    Type: Application
    Filed: September 20, 2011
    Publication date: July 11, 2013
    Inventors: Zehong WAN, Xiaomio Zhang, Zhaolong Tong, Kai Long, Sarah E. Dowdell, Eric Steven Manas, Krista Beaver Goodman